SCHEMBL3015155

SCHEMBL3015155

O=S(=O)(c1ccc(Cl)c(Cl)c1)C1CCN(c2nc(Cc3ccccc3)cs2)CC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.41
KCNH2 Q12809 2/20 0.38
HTR2C P28335 1/20 0.38
HRH4 Q9H3N8 2/20 0.36
HTR6 P50406 1/20 0.36
LMNA P02545 2/20 0.36
DNM1L O00429 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GBA1 P04062 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
AR P10275 1/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35
ADRB3 P13945 1/20 0.35
SPR P35270 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017117 0.92 MAPT (0.38) HTR2AKCNH2HTR2CLMNAL3MBTL1
SCHEMBL3013801 0.92 L3MBTL1 (0.39) HTR2ALMNADNM1LL3MBTL1KMT2A
SCHEMBL3013788 0.92 HTR2A (0.39) HTR2AKCNH2HTR2CHRH4LMNA
SCHEMBL3019243 0.91 L3MBTL1 (0.38) HTR2AKCNH2HTR2CLMNADNM1L
SCHEMBL3010771 0.91 HTR2A (0.34) HTR2AKCNH2HTR2CLMNAL3MBTL1
SCHEMBL3010484 0.90 THRB (0.42) LMNADNM1LL3MBTL1ARSMN1; SMN2
SCHEMBL3016660 0.90 GBA1 (0.38) LMNADNM1LL3MBTL1GBA1KMT2A
SCHEMBL3019996 0.90 SCN8A (0.37) HTR2ALMNADNM1LL3MBTL1GBA1
SCHEMBL3018148 0.89 VCAM1 (0.42) HTR2ADNM1LMAPK1
SCHEMBL3014724 0.89 HTR2A (0.46) HTR2AKCNH2HTR2CLMNAGBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HTR2A 752/4885KCNH2 3130/4885HTR2C 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.